TALEN

TALEN1-nr1h3

ID
ZDB-TALEN-141208-1
Name
TALEN1-nr1h3
Previous Names
None
Target
Target Sequence 1
5' - GGCTTTCATTACAATGTGCT - 3'
Target Sequence 2
5' - GCGTCTGAAGAAACCTTT - 3'
Disclaimer
Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.
Note
None
Genome Resources
None
Target Location
Constructs
No data available
Genomic Features
Genomic Feature Affected Genomic Regions
z101a nr1h3
z102a nr1h3
Expression
Gene expression in Wild Types + TALEN1-nr1h3
No data available
Phenotype
Phenotype resulting from TALEN1-nr1h3
No data available
Phenotype of all Fish created by or utilizing TALEN1-nr1h3
Phenotype Fish Conditions Figures
male organism intestine fasn expression increased amount, abnormal nr1h3z101a/z101a control Fig. 5 from Benítez-Santana et al., 2017
male organism liver abca1a expression decreased amount, abnormal nr1h3z101a/z101a control Fig. 5 from Benítez-Santana et al., 2017
liver cholesteryl ester increased amount, abnormal nr1h3z101a/z101a high cholesterol Fig. 4 from Benítez-Santana et al., 2017
female organism lipoprotein lipase activity decreased process quality, abnormal nr1h3z101a/z101a chemical treatment by injection: tyloxapol Fig. 2 from Benítez-Santana et al., 2017
vasculature lipid increased amount, exacerbated nr1h3z101a/z101a chemical treatment by gavage: cholesteryl oleate, chemical treatment by gavage: triolein, chemical treatment by gavage: CholEsteryl BODIPY 542/563 C11 Fig. 1 from Benítez-Santana et al., 2017
female organism intestine srebf1 expression increased amount, abnormal nr1h3z101a/z101a control Fig. 5 from Benítez-Santana et al., 2017
liver cholesterol increased amount, abnormal nr1h3z101a/z101a high cholesterol Fig. 4 from Benítez-Santana et al., 2017
female organism intestine acaca expression increased amount, abnormal nr1h3z101a/z101a control Fig. 5 from Benítez-Santana et al., 2017
blood plasma cholesterol increased amount, exacerbated nr1h3z101a/z101a high cholesterol Fig. 3 from Benítez-Santana et al., 2017
blood plasma triglyceride increased amount, abnormal nr1h3z101a/z101a chemical treatment by gavage: cholesteryl oleate, chemical treatment by gavage: triolein, chemical treatment by gavage: CholEsteryl BODIPY 542/563 C11 Fig. 2 from Benítez-Santana et al., 2017
male organism intestine acaca expression decreased amount, abnormal nr1h3z101a/z101a control Fig. 5 from Benítez-Santana et al., 2017
male organism liver abca1b expression decreased amount, abnormal nr1h3z101a/z101a control Fig. 5 from Benítez-Santana et al., 2017
intestinal lipid absorption increased occurrence, abnormal nr1h3z101a/z101a chemical treatment by gavage: cholesteryl oleate, chemical treatment by gavage: triolein, chemical treatment by gavage: CholEsteryl BODIPY 542/563 C11 Fig. 1 from Benítez-Santana et al., 2017
male organism intestine srebf1 expression increased amount, abnormal nr1h3z101a/z101a control Fig. 5 from Benítez-Santana et al., 2017
male organism triglyceride increased amount, abnormal nr1h3z101a/z101a chemical treatment by gavage: cholesteryl oleate, chemical treatment by gavage: triolein, chemical treatment by gavage: CholEsteryl BODIPY 542/563 C11 Fig. 2 from Benítez-Santana et al., 2017
female organism liver abca1a expression decreased amount, abnormal nr1h3z101a/z101a control Fig. 5 from Benítez-Santana et al., 2017
Citations